Archive: Company News
Company News: Curetis Announces Change of the Composition of Its Supervisory Board
— Holger Reithinger resigns as member of the Supervisory Board
— Company exploring options to further evolve Board at upcoming 2018 AGM
Curetis N.V. (the “Company” and, together with Curetis GmbH and Curetis USA Inc., “Curetis“), a developer of next-level molecular diagnostic solutions, today announced that Dr. Holger Reithinger, General Partner at Forbion, resigns from Curetis’ Supervisory Board effective today, April 30, 2018.
Company News: Curetis Publishes Full-Year 2017 Financial Results and Updated Guidance For 2018
– Received U.S. FDA clearance for Unyvero System and Unyvero LRT Cartridge; commercial U.S. roll-out initiated
– Launched two novel CE-IVD marked Unyvero Applications
– Strengthened global commercial footprint; expanded installed base
Curetis N.V. (the “Company” and, together with Curetis GmbH, “Curetis“), a developer of next-level molecular diagnostic solutions, today announced financial results for the twelve months ended December 31, 2017 and provided an updated guidance for 2018.
Company News: Curetis to Raise EUR 4.1 Million in Equity Offering with Access to Additional USD 10 million in Equity Over 36 Months
– Company to Issue 854,166 New Shares at EUR 4.80 Per Share
This announcement contains inside information within the meaning of article 7(1) of the EU Market Abuse Directive.
Curetis N.V. (the “Company” and, together with Curetis GmbH, “Curetis“), a developer of next-level molecular diagnostic solutions, today announced that it has obtained commitments from qualified investors in Europe and the United States to subscribe for 854,166 new ordinary shares (the “Offer Shares”) of the Company (the “Offering”).
Company News: ISA Pharmaceuticals’ ISA101 Studied in Phase II Oropharyngeal Cancer Combination Trial at MD Anderson Cancer Center
ISA Pharmaceuticals B.V., a clinical-stage immunotherapy company focusing on rationally designed immunotherapeutics against cancer and persistent viral infections, today announced the start of a Phase II combination trial of its lead compound ISA101b and Pfizer´s 4-1BB agonist Utomilumab, which will be sponsored and conducted by The University of Texas MD Anderson Cancer Center (Houston, TX).